Epizyme, Inc
EPZM
EPZM was delisted on the 11th of August, 2022.
83 hedge funds and large institutions have $699M invested in Epizyme, Inc in 2014 Q2 according to their latest regulatory filings, with 20 funds opening new positions, 33 increasing their positions, 18 reducing their positions, and 12 closing their positions.
135% more call options, than puts
Call options by funds: $737K | Put options by funds: $314K
83% more repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 18
67% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 12
42% more capital invested
Capital invested by funds: $494M → $699M (+$205M)
11% more funds holding
Funds holding: 75 → 83 (+8)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
QF
QVT Financial
New York
|
+$12.5M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$12.4M |
| 3 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
+$6.13M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$3.53M |
| 5 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$2.67M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citigroup
New York
|
-$9.23M |
| 2 |
NI
Numeric Investors
Boston,
Massachusetts
|
-$5.87M |
| 3 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$2.63M |
| 4 |
SM
Sabby Management
Miami Beach,
Florida
|
-$2.41M |
| 5 |
JP Morgan Chase
New York
|
-$2.21M |
EPZM Hedge Fund Activity: Q2 2014 in Review
83 of the 3,479 institutional investors tracked by Wall St. Rank reported a position in Epizyme, Inc (EPZM) for Q2 2014, worth a combined $699M — up 42% from $494M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new EPZM positions and 12 closed out — a net gain of 8 holders — while 33 added to existing stakes and 18 trimmed.
The largest buyer was QVT Financial, adding an estimated $12.5M. The largest seller was Citigroup, cutting an estimated $9.23M.
- 83 institutional investors held Epizyme, Inc (EPZM) as of Q2 2014, up from 75 in Q1 2014.
- Funds reported $699M of Epizyme, Inc stock for Q2 2014, up 42% quarter-over-quarter.
- 20 funds opened new Epizyme, Inc positions in Q2 2014 and 12 closed out, a net change of +8 holders.
- The largest Epizyme, Inc buyer in Q2 2014 was QVT Financial, an estimated $12.5M added.
- The largest Epizyme, Inc seller in Q2 2014 was Citigroup, an estimated $9.23M sold.
Based on aggregated 13F filings for Q2 2014.